A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma

Abstract

BACKGROUND To evaluate the impact of treatment on health states that affect patients' quality of life in advanced follicular lymphoma. METHODS A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marcus et al, 2008). RESULTS Cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP)-treated patients gained a mean of 15.17 months in TWiST, 8.33 months in Q-TwiST, and 11.30 months less in disease relapse, without increase in toxicity compared with cyclophosphamide, vincristine, and prednisone (CVP)-treated patients. CONCLUSION Rituximab plus CVP-treated patients reached a significant and clinically meaningful improvement within 12 months in quality-adjusted survival compared with CVP.

DOI: 10.1038/sj.bjc.6605443

Extracted Key Phrases

4 Figures and Tables

Cite this paper

@article{Marcus2010AQS, title={A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma}, author={Robert Marcus and Rick Aultman and Fred Jost}, journal={British Journal of Cancer}, year={2010}, volume={102}, pages={19 - 22} }